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LETTER TO THE EDITOR
Amiens, 17/08/2005
SEVERE Pneumocystis PNEUMONIA IN A RENAL TRANSPLANT RECIPIENT AFTER
LONG TERM MYCOPHENOLATE MOFETIL TREATMENT
Dear Sir,
We read with interest the article by AZEVEDO et al.2 recently published in the REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SÃO
PAULO (Journal of the São Paulo Institute of Tropical Medicine)2. The authors suggested that mycophenolate mofetil (MMF) may have a protective
role against Pneumocystis pneumonia (PCP). Through a retrospective study, they noticed no PCP occurrence in a cohort of renal transplant recipients
treated with MMF, despite the absence of trimethoprim-sulfamethoxazole (TMS) prophylaxis. We report herein a case of severe PCP which occurred
in a renal transplant recipient after long-term MMF treatment and describe the genotyping of the fungus detected in this patient.
The patient was a 29 year-old man who underwent a renal transplantation because of chronic renal failure related to Berger’s disease (IgA
nephropathy). The underlying conditions up to 18 months after the renal transplantation were: absence of efficient PCP prophylaxis related to the
lack of patient compliance; an immunosuppressive therapy which consisted of tacrolimus (6 mg/d), MMF (1 g/d), and prednisone (15 mg/d). At
the end of that period, MMF treatment was replaced with azathioprine (100 mg/d). Six months later, the patient presented an acute alveolo-
interstitial syndrome with severe dyspnoea, cough and fever leading to hospitalization in an intensive care unit. The examination of a bronchoalveolar
lavage (BAL) specimen by using methanol-Giemsa stain and immunofluorescence assay (Biorad, France) resulted in a diagnosis of PCP in the
presence of P. jirovecii cystic and trophic forms and in the absence of other microorganisms. The patient was treated with cotrimoxazole at 50 mg/
kg/d (dosage adapted to renal failure) and methylprednisolone at 80 mg/d. One week later, because of progressive deterioration, a second BAL
was performed in which microscopic P. jirovecii detection remained positive. Cotrimoxazole dosage was increased to 75 mg/kg/d and associated
with intravenous pentamidine at 100 mg/d. In the absence of improvement, a third BAL was performed in which P. jirovecii organisms were still
detectable in association with Streptococcus pneumoniae and HSV 1. Advancing hypoxemia required connection to mechanical ventilation,
increased dosages of cotrimoxazole and pentamidine (up to 100 mg/kg/d and 150 mg/day respectively), and treatment with aciclovir (15 mg/d)
and cefotaxime (3 g/d). Despite these treatments, the patient died after a 27 day hospitalization. Sediments of the three subsequent BALs were
stored at -80 °C for further genotyping.
A multilocus genotyping was performed. As previously described, it was based on the internal transcribed spacer (ITS) 1 and ITS 2 locus14, the
locus of the dihydropteroate synthase (DHPS)14, which is the enzymatic target of sulfonamide drugs, and sequence analysis of the mitochondrial
large sub-unit (mtLSU) rRNA locus7,15,16. In the three BAL specimens, a single and identical ITS 1 and 2 allele combination, B1a4, wild sequences
of DHPS locus, and identical mtLSUrRNA sequences were observed. Thus, by using a multilocus genotyping at three independent loci, a single
P. jirovecii genotype was identified, suggesting that the infection was clonal due to only one P. jirovecii strain.
In this study, we reported a case of severe PCP in a renal transplant recipient which occurred after long-term MMF treatment. It is noteworthy
that the patient did not develop the infection until MMF treatment was interrupted, despite the absence of efficient PCP prophylaxis. PCP appears
to be rare in patients with MMF treatment as revealed by HUSAIN & SINGH in a review article: in four controlled trials, none of a total 1068 renal
transplant recipients who received MMF developed PCP6. These results suggest that the drug is active against P. jirovecii (human derived
Pneumocystis) as it was established in rodent models for P. carinii (rat derived Pneumocystis)12. However, discontinuation of P. jirovecii prophylaxis
for patients receiving MMF is not yet recommended.
We identified a single P. jirovecii genotype in three subsequent BALs performed during this PCP episode. The analysis of the DHPS locus was
included in the multi-locus system we chose, since it has previously been suggested that P. jirovecii DHPS mutants have a significant impact on
the outcome of PCP and patient mortality3. For our patient, it was improbable that death was related to such a correlation as no P. jirovecii DHPS
mutant was detected. We identified a rare allele combination at the ITS locus. The allele combination B1a4 [which corresponds to Jf as described
by LEE et al.8 (GenBank accession numbers, AF 013815 and AF 013826)] has only been reported in six instances, five concerning PCP cases
among patients with HIV1,4,5,8 and one concerning a primary infection with P. jirovecii developed by infants13. A relationship between ITS allele
combination and virulence has been suggested by MILLER & WAKEFIELD who identified the combination A2c1 as a cause of severe pneumonia10.
However, the ITS allele combination B1a4 was not part of the panel investigated by MILLER et al. because of its rare occurrence.
In a previous study, by analyzing the ITS locus and sequencing a number of clones from three to five for each specimen, we observed a frequency
of mixed infections up to 66%11, showing that P. jirovecii infection is not clonal in most cases. Conversely, in the present study we identified a single
and identical ITS allele combination in one patient with PCP, despite examination of three BAL specimens retrieved over a 15 day period, and a high
number of clones (a total of 18, data not shown). Furthermore, at each of the mtLSUrRNA and the DHPS loci, identical sequences were also detected.
Our genotyping approach, which combined cloning and multi-locus sequence analysis performed on iterative BAL specimens within the same PCP
episode reduced the risk of underlooking genotypes and enabled us to assess the presence of a single type in our patient.
However, we should consider the possibility that initially the infection may not have been clonal. The MMF target is the inositol monophosphate
dehydrogenase (IMPDH) which appears to have different variants17 that may conserve activity despite MMF treatment. Thus, the MMF treatment may
have killed off susceptible strains leaving resistant strains that corresponded to the single genotype finally detected in our patient. In this case, the patient
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may have harbored the fungus, at least over a 6-month period after MMF treatment interruption and before developing the present PCP episode. This is
consistent with previous studies which established that immunosuppressed patients can frequently be colonized by the fungus11. In fact, it cannot be ruled
out that the P. jirovecii genotype corresponds to virulent organisms proliferating initially in a clonal context or secondarily after selection by MMF
treatment. The severity of PCP in our patient may be partly related to his past history of long-term MMF treatment. The present case-report pleads in
favor of P. jirovecii prophylaxis maintenance in transplant recipients even if the immunosuppressive therapy is based on MMF.
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